✓ No fee unless you win✓ Free & confidential review✓ Board-certified trial attorney

Depo-Provera November 30 Registration Deadline: What If a Meningioma Claim Falls Outside the Settlement?

Last reviewed: October 6,
2026

There is now a real date in
the Depo-Provera meningioma
MDL that people are asking
about: November 30, 2026.

That date appears in Case
Management Order No. 14. The
order says the court
understands that claimants
must register by November 30
if they want to participate
in the settlement program.
It also says people who are
later identified as
ineligible will be
identified to the court.

Those two pieces belong
together. The order is not
saying every possible
Depo-Provera meningioma
claim is over. It is saying
the court expects a
settlement program for a
large group of pending MDL
plaintiffs, and it is also
preparing for claims that do
not fit that program.

For a woman diagnosed with
an intracranial meningioma
after Depo-Provera,
Depo-SubQ Provera 104, or
generic depot
medroxyprogesterone acetate,
the immediate question is
not a slogan about
settlement. It is more
basic: do the records show
the product, the timing, the
diagnosis, and the injury
clearly enough for the lane
the claim is actually in?

Our main Depo-Provera
lawsuit
page
covers the broader
allegations in MDL 3140.
This article is about the
November 30
settlement-registration
language and the people who
may need to think about what
happens outside that lane.

What November 30 means in the court order

Case Management Order No. 14
says MDL plaintiffs' lead
counsel and the Pfizer
defendants entered into a
settlement program
memorialized in July 2026.
The court wrote that the
program will offer a
substantial percentage of
plaintiffs with pending MDL
cases the opportunity to
resolve their claims.

Then comes the date. The
order says the deadline for
claimants to register to
participate in the
settlement program is
November 30, 2026.

That is a settlement-program
date. It is not the same
thing as a public promise
that every person with a
meningioma diagnosis will be
paid. It is not a published
compensation chart. It is
not a substitute for
state-law deadline analysis.

It also should not be
ignored. If a claim is
supposed to be in the
settlement program,
registration and
documentation are not
clerical afterthoughts. They
are the doorway into the
process.

Why an outside-the-program claim can be different

Some claims may not fit. The
public order does not spell
out every eligibility rule,
and we are not going to
pretend it does.

A claim could run into
questions about timing,
product proof, diagnosis
records, who represented the
claimant and when, or other
program criteria. A claimant
may also choose not to
participate if an opt-out
right applies. The details
matter.

Once a claim is outside the
settlement program, the work
can look less like
settlement administration
and more like litigation
again. That may mean
discovery, case-specific
proof, court deadlines,
expert issues, and
statute-of-limitations
questions.

Case Management Order No. 14
was written for that exact
problem: ongoing litigation
after the settlement
program. The order recorded
6,289 pending MDL cases at
that time. It also described
how the court planned to
manage cases that continue.

So the clean takeaway is
this: settlement activity
does not make records less
important. It makes them
urgent.

Records we would look for first

Start with the shots. A
memory that someone used
Depo-Provera for years may
be true, but a claim usually
needs documents.

Look for:

OB/GYN, health department, family-planning, primary-care, or campus-clinic records;
pharmacy benefit records or insurance explanations of benefits showing DMPA, Depo-Provera, Depo-SubQ Provera 104, or an authorized generic;
old portal entries, appointment summaries, medication administration logs, or billing records; and
records under a former last name, old address, or closed clinic system.

Then build the tumor
timeline.

Look for:

MRI or CT reports identifying an intracranial meningioma;
neurology, neurosurgery, radiation-oncology, operative, or pathology records;
follow-up imaging showing monitoring, growth, surgery, or radiation; and
records showing symptoms, treatment, missed work, caregiving needs, or limits in ordinary life.

Our September article on
Depo-Provera settlement
administration
orders
explains the administrator
roles. This update adds the
deadline point. Whether a
claim is reviewed by an
administrator or litigated
outside the program, thin
records create problems.

What not to assume

Do not assume November 30 is
the deadline to file every
new lawsuit. The court order
describes registration for
the settlement program.
Filing deadlines are
different and depend on the
state, the diagnosis date,
discovery rules, and the
facts.

Do not assume the settlement
is an admission of fault.
Case Management Order No. 14
says there is no admission
of fault or liability by the
defendants in connection
with the settlement.

Do not assume the MDL status
proves an individual claim.
The Northern District of
Florida's MDL page says the
cases share allegations that
injectable Depo-Provera or
generic equivalents can
cause one or more
meningiomas. It also notes
that defendants maintain the
medication is safe and
effective.

And do not make medical
decisions because of a
lawsuit update. Pfizer's
current prescribing
information includes a
meningioma warning and says
Depo-Provera CI should be
discontinued if a meningioma
is diagnosed, but
contraceptive and treatment
decisions belong with a
medical professional who
knows the patient.

Short FAQ

Is November 30, 2026 the deadline to file a new Depo-Provera lawsuit?

Not necessarily. Case
Management Order No. 14 uses
that date for registration
in the settlement program.
Filing deadlines are
separate and may vary by
state and by the facts of
the diagnosis.

Does the settlement cover every Depo-Provera meningioma claim?

No public order says that.
The court said the program
will offer a substantial
percentage of pending MDL
plaintiffs the chance to
resolve their claims, and it
also planned for claims that
remain after the program.

What should I gather if I am not sure where my claim fits?

Start with proof of
injections and proof of
diagnosis: clinic or
pharmacy records for
Depo-Provera or generic
DMPA, MRI or CT reports,
neurosurgery or pathology
records, and follow-up
treatment records.

Sources

Attorney Advertising. This
article is for general
information only. It is not
medical advice or legal
advice. Reading it or
submitting a form does not
create an attorney-client
relationship. Every claim
depends on the person's
records, exposure history,
deadlines, settlement
criteria, and applicable
law.

Robert B. Baker, Board-Certified Civil Trial Attorney

Claims reviewed by Baker Legal Team
Robert B. Baker, Esq., B.C.S. — Board-Certified Civil Trial Lawyer. 30+ years of trial experience, more than $400 million recovered for clients. About Robert Baker →